Title: BRCA1 and BRCA2 mutations in ovarian cancer patients treated with olaparib

Abstract:
Patients with BRCA1 or BRCA2 mutations receiving olaparib showed improved progression-free survival. Symptoms like abdominal pain and bloating were common. Olaparib treatment led to reduced tumor size in 60% of patients. Hematologic toxicities were observed.